Semaglutide Clinical Trials
44 recruitingDrug
Phase 217Phase 18Phase 38Phase 47Not Applicable4
Showing 1–20 of 44 trials
Recruiting
Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Obesity
Kailera1,200 enrolled34 locationsNCT07284979
Recruiting
Phase 1
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Obesity
Novo Nordisk A/S75 enrolled1 locationNCT07225816
Recruiting
Phase 2
Glutide for Ending Methamphetamine
Methamphetamine Dependence
San Francisco Department of Public Health162 enrolled1 locationNCT07204249
Recruiting
Weight Loss in Adults Using Semaglutide (Real-world Study)
ObesityOverweight
Novo Nordisk A/S35,000 enrolled2 locationsNCT07627074
Recruiting
Phase 2
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Type 1 DiabetesDiabetic Kidney Disease
University of Washington60 enrolled4 locationsNCT05822609
Recruiting
Phase 3
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
ObesityType 2 Diabetes
Novo Nordisk A/S2,500 enrolled303 locationsNCT07564414
Recruiting
Phase 1
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Obesity
Boehringer Ingelheim30 enrolled1 locationNCT05202353
Recruiting
Phase 2
Semaglutide Therapy for Alcohol Reduction (STAR)
Alcohol Use DisorderAddiction
National Institute on Drug Abuse (NIDA)80 enrolled1 locationNCT06015893
Recruiting
Not Applicable
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Obesity, OverweightType 2 Diabetes (T2DM)Obesity (Disorder)
GT Metabolic Solutions, Inc.20 enrolled1 locationNCT07317115
Recruiting
Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Novo Nordisk A/S270 enrolled63 locationsNCT07415954
Recruiting
Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)84 enrolled1 locationNCT03884075
Recruiting
Phase 3
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
Klinefelter Syndrome
Georgios Papadakis150 enrolled1 locationNCT05586802
Recruiting
Phase 3
Semaglutide for Smoking Cessation in Patients With Diabetes
Diabetes Mellitus, Type 2Tobacco DependenceNicotine Addiction
Ottawa Heart Institute Research Corporation100 enrolled1 locationNCT07059377
Recruiting
Phase 1
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Obesity
Novo Nordisk A/S100 enrolled1 locationNCT07527195
Recruiting
Phase 3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
ObesityOverweight
Novo Nordisk A/S460 enrolled119 locationsNCT07253285
Recruiting
Phase 4
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Obesity and Obesity-related Medical Conditions
Ali Aminian125 enrolled1 locationNCT06803888
Recruiting
Phase 2
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
Cocaine Use Disorder
The University of Texas Health Science Center, Houston75 enrolled1 locationNCT07227948
Recruiting
Phase 4
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
Prediabetes
The University of Texas Health Science Center, Houston300 enrolled1 locationNCT05119179
Recruiting
Phase 2
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
Diabetes
Mostafa Bahaa105 enrolled1 locationNCT06762314
Recruiting
Phase 2
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
Type 2 Diabetes Mellitus
Hoffmann-La Roche240 enrolled51 locationsNCT07112872